Physician profile
Gates Burton Colbert
NPI 1992017545
$827,650.79
in general payments reported to CMS, 2019-2025
51 companies · $97K in 2025
The $97K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $50K · 2021: $77K · 2022: $223K · 2023: $173K · 2024: $98K · 2025: $97K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $265K · Consulting Fee: $46K · Travel and Lodging: $35K · Food and Beverage: $22K · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $265,030.75 |
| Consulting Fee | $46,386.69 |
| Travel and Lodging | $35,178.56 |
| Food and Beverage | $21,950.20 |
| Education | $164.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $255,273.71 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $161,602.48 | 2019-2025 | Farxiga, Lokelma |
| Glaxosmithkline, LLC. | $120,822.29 | 2020-2025 | Benlysta, Jesduvroq |
| Daiichi Sankyo INC. | $99,194.20 | 2019-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $66,162.39 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $33,679.35 | 2019-2021 | |
| Akebia Therapeutics INC | $24,331.36 | 2020-2025 | Vafseo |
| Travere Therapeutics, INC. | $11,162.37 | 2019-2025 | Filspari |
| Boehringer Ingelheim International Gmbh | $11,025.00 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,791.20 | 2022-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $7,046.47 | 2021-2025 | Jynarque |
| Janssen Global Services, LLC | $5,404.85 | 2022 | |
| Idorsia Pharmaceuticals US INC | $4,084.95 | 2025 | Tryvio |
| Calliditas Therapeutics US INC. | $2,655.31 | 2022-2025 | Tarpeyo |
| Recor Medical INC | $2,013.07 | 2025 | Paradise Ultrasound Renal Denervation System |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,612.99 | 2019-2025 | Krystexxa, Tavneos, Epogen |
| Alexion Pharmaceuticals, INC. | $1,510.00 | 2019-2025 | Ultomiris, Soliris, Strensiq |
| Opko Pharmaceuticals, LLC | $1,262.75 | 2019-2025 | Rayaldee |
| La Jolla Pharmaceutical Company | $1,126.50 | 2019-2023 | Giapreza |
| Otsuka America Pharmaceutical, INC. | $1,114.43 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $1,064.65 | 2020-2025 | Acthar |
| Fresenius USA Marketing, INC. | $786.15 | 2019-2025 | Velphoro, Crit-Line, Velphoro |
| Veloxis Pharmaceuticals, INC. | $640.01 | 2019-2025 | Envarsus |
| Ani Pharmaceuticals, INC. | $441.24 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $435.78 | 2022-2025 | Lupkynis |
| Ardelyx, INC. | $374.09 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Horizon Therapeutics Plc | $364.56 | 2019-2023 | Krystexxa |
| Cormedix INC. | $324.70 | 2024-2025 | Defencath, Defencath |
| Apellis Pharmaceuticals, INC. | $309.86 | 2025 | Empaveli |
| Nxstage Medical, INC. | $276.39 | 2019-2025 | Nxstage System One, Nxstage Pureflow Solution, Nxstage Cartridge Express |
| Renalytix Ai, INC. | $243.35 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Mallinckrodt Enterprises LLC | $192.19 | 2019 | |
| Novo Nordisk INC | $164.89 | 2024-2025 | Wegovy, Ozempic |
| W. L. Gore & Associates, INC. | $136.14 | 2021 | |
| Astrazeneca Uk Limited | $129.89 | 2025 | Lokelma |
| Pfizer INC. | $120.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $99.71 | 2024-2025 | |
| Outset Medical INC | $95.13 | 2019 | |
| Alnylam Pharmaceuticals INC. | $94.27 | 2023 | Givlaari, Oxlumo |
| Chiesi USA, INC. | $69.73 | 2019-2022 | |
| Lilly USA, LLC | $63.61 | 2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $60.47 | 2020-2021 | |
| Potrero Medical, INC. | $60.36 | 2021 | |
| Recordati_rare_diseases_inc. | $44.19 | 2023-2024 | Cystadrops |
| Scpharmaceuticals INC. | $38.77 | 2025 | |
| Shield Therapeutics INC | $38.70 | 2022 | |
| Baxter Healthcare | $31.29 | 2019 | |
| Genentech USA, INC. | $27.99 | 2022-2025 | Gazyva |
| Eagle Pharmaceuticals, INC. | $18.04 | 2023 | |
| Shire North American Group INC | $17.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gates Colbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.